Actively Recruiting
Theranostic Applications of Radionuclides in Prostate Cancer
Led by Guilin Medical University, China · Updated on 2026-04-30
100
Participants Needed
1
Research Sites
208 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The objective of the study is to construct a noninvasive approach ACP3 targeted PET/CT to detect tumor lesions in patients with prostate cancer and to compare with PSMA/FDG PET/CT.
CONDITIONS
Official Title
Theranostic Applications of Radionuclides in Prostate Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adult patients (aged 18 years or older)
- Patients with newly diagnosed, highly suspected recurrence or previously treated metastases of prostate cancer (supported by MRI, CT, tumor markers, or pathology report)
- Patients scheduled for both standard-of-care imaging (PSMA/FDG PET/CT) and ACP3 PET/CT scans
- Patients able to provide informed consent (signed by participant, parent, or legal representative) and assent per ethics guidelines
You will not qualify if you...
- Unable or unwilling to provide written informed consent by the participant or legal representative
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
The First Affliated Hospital of Guilin Medical University
Guilin, Guangxi, China, 541001
Actively Recruiting
Research Team
X
Xingyu Mu, PhD
CONTACT
W
Wei Fu
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
DIAGNOSTIC
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here